Efficacy and safety of lacosamide as first add-on or later adjunctive treatment for uncontrolled partial-onset seizures

Purpose To evaluate the efficacy and safety of lacosamide administered as either first add-on or later add-on antiepileptic drug (AED) therapy for patients with uncontrolled partial-onset seizures (POS). Methods In this open-label, multicentre trial, patients with POS initiated oral lacosamide (titr...

ver descrição completa

Detalhes bibliográficos
Autores: Zadeh, Wendy Waldman, Escartín Siquier, Antonio E, Byrnes, William, Tennigkeit, Frank, Borghs, Simon, Li, Ting, Dedeken, Peter, De Backer, Marc
Formato: artículo
Fecha de publicación:2015
País:España
Recursos:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:299412
Acesso em linha:https://ddd.uab.cat/record/299412
https://dx.doi.org/urn:doi:10.1016/j.seizure.2015.07.001
Access Level:acceso abierto
Palavra-chave:Focal epilepsy
Lacosamide
Quality of life
Seizure freedom
id ES_fa87861a2c25a32e83c8f6a8569d3f8e
oai_identifier_str oai:ddd.uab.cat:299412
network_acronym_str ES
network_name_str España
repository_id_str
spelling Efficacy and safety of lacosamide as first add-on or later adjunctive treatment for uncontrolled partial-onset seizuresA multicentre open-label trialZadeh, Wendy WaldmanEscartín Siquier, Antonio EByrnes, WilliamTennigkeit, FrankBorghs, SimonLi, TingDedeken, PeterDe Backer, MarcFocal epilepsyLacosamideQuality of lifeSeizure freedomPurpose To evaluate the efficacy and safety of lacosamide administered as either first add-on or later add-on antiepileptic drug (AED) therapy for patients with uncontrolled partial-onset seizures (POS). Methods In this open-label, multicentre trial, patients with POS initiated oral lacosamide (titrated to 400 mg/day) either as add-on to first AED monotherapy, or as later add-on to 1-3 concomitant AEDs after 2 previous AEDs. The primary efficacy variable was the proportion of patients achieving seizure freedom for the first 12 weeks of the 24-week Maintenance Phase. Results 456 patients received 1 dose of lacosamide (96 as first add-on, 360 as later add-on). In the first add-on cohort, 27/72 (37.5%) patients completed 12 weeks treatment and remained seizure-free; 18/68 (26.5%) remained seizure-free after 24 weeks. 64/91 (70.3%) patients achieved 50% reduction in seizure frequency during maintenance treatment. This was accompanied by a mean 7.1 ± 16.00 point improvement from Baseline in the Quality of Life Inventory in Epilepsy (QOLIE-31-P) total score for 24-week completers, with improvement reported in all subscales. Most common treatment-emergent adverse events (TEAEs) were dizziness (31.3%) and headache (13.5%). In the later add-on cohort, 39/261 (14.9%) and 29/249 (11.6%) patients remained seizure-free after completing 12 and 24 weeks' treatment, respectively. 178/353 (50.4%) patients achieved 50% reduction in seizure frequency during maintenance treatment. Mean change in QOLIE-31-P total score was 4.8 ± 14.74 points among 24-week completers. Common TEAEs were dizziness (33.6%), somnolence (15.0%) and headache (11.4%). Conclusions Lacosamide initiated as first add-on treatment was efficacious and well tolerated in patients with uncontrolled POS.Universitat Autònoma de Barcelona 22015-01-0120152015-01-01Articlehttp://purl.org/coar/resource_type/c_6501VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttps://ddd.uab.cat/record/299412https://dx.doi.org/urn:doi:10.1016/j.seizure.2015.07.001reponame:Dipòsit Digital de Documents de la UABinstname:Universitat Autònoma de BarcelonaInglésengopen accesshttp://purl.org/coar/access_right/c_abf2Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.https://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccessoai:ddd.uab.cat:2994122026-06-06T12:50:31Z
dc.title.none.fl_str_mv Efficacy and safety of lacosamide as first add-on or later adjunctive treatment for uncontrolled partial-onset seizures
A multicentre open-label trial
title Efficacy and safety of lacosamide as first add-on or later adjunctive treatment for uncontrolled partial-onset seizures
spellingShingle Efficacy and safety of lacosamide as first add-on or later adjunctive treatment for uncontrolled partial-onset seizures
Zadeh, Wendy Waldman
Focal epilepsy
Lacosamide
Quality of life
Seizure freedom
title_short Efficacy and safety of lacosamide as first add-on or later adjunctive treatment for uncontrolled partial-onset seizures
title_full Efficacy and safety of lacosamide as first add-on or later adjunctive treatment for uncontrolled partial-onset seizures
title_fullStr Efficacy and safety of lacosamide as first add-on or later adjunctive treatment for uncontrolled partial-onset seizures
title_full_unstemmed Efficacy and safety of lacosamide as first add-on or later adjunctive treatment for uncontrolled partial-onset seizures
title_sort Efficacy and safety of lacosamide as first add-on or later adjunctive treatment for uncontrolled partial-onset seizures
dc.creator.none.fl_str_mv Zadeh, Wendy Waldman
Escartín Siquier, Antonio E
Byrnes, William
Tennigkeit, Frank
Borghs, Simon
Li, Ting
Dedeken, Peter
De Backer, Marc
author Zadeh, Wendy Waldman
author_facet Zadeh, Wendy Waldman
Escartín Siquier, Antonio E
Byrnes, William
Tennigkeit, Frank
Borghs, Simon
Li, Ting
Dedeken, Peter
De Backer, Marc
author_role author
author2 Escartín Siquier, Antonio E
Byrnes, William
Tennigkeit, Frank
Borghs, Simon
Li, Ting
Dedeken, Peter
De Backer, Marc
author2_role author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Universitat Autònoma de Barcelona
dc.subject.none.fl_str_mv Focal epilepsy
Lacosamide
Quality of life
Seizure freedom
topic Focal epilepsy
Lacosamide
Quality of life
Seizure freedom
description Purpose To evaluate the efficacy and safety of lacosamide administered as either first add-on or later add-on antiepileptic drug (AED) therapy for patients with uncontrolled partial-onset seizures (POS). Methods In this open-label, multicentre trial, patients with POS initiated oral lacosamide (titrated to 400 mg/day) either as add-on to first AED monotherapy, or as later add-on to 1-3 concomitant AEDs after 2 previous AEDs. The primary efficacy variable was the proportion of patients achieving seizure freedom for the first 12 weeks of the 24-week Maintenance Phase. Results 456 patients received 1 dose of lacosamide (96 as first add-on, 360 as later add-on). In the first add-on cohort, 27/72 (37.5%) patients completed 12 weeks treatment and remained seizure-free; 18/68 (26.5%) remained seizure-free after 24 weeks. 64/91 (70.3%) patients achieved 50% reduction in seizure frequency during maintenance treatment. This was accompanied by a mean 7.1 ± 16.00 point improvement from Baseline in the Quality of Life Inventory in Epilepsy (QOLIE-31-P) total score for 24-week completers, with improvement reported in all subscales. Most common treatment-emergent adverse events (TEAEs) were dizziness (31.3%) and headache (13.5%). In the later add-on cohort, 39/261 (14.9%) and 29/249 (11.6%) patients remained seizure-free after completing 12 and 24 weeks' treatment, respectively. 178/353 (50.4%) patients achieved 50% reduction in seizure frequency during maintenance treatment. Mean change in QOLIE-31-P total score was 4.8 ± 14.74 points among 24-week completers. Common TEAEs were dizziness (33.6%), somnolence (15.0%) and headache (11.4%). Conclusions Lacosamide initiated as first add-on treatment was efficacious and well tolerated in patients with uncontrolled POS.
publishDate 2015
dc.date.none.fl_str_mv 2
2015-01-01
2015
2015-01-01
dc.type.none.fl_str_mv Article
http://purl.org/coar/resource_type/c_6501
VoR
http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://ddd.uab.cat/record/299412
https://dx.doi.org/urn:doi:10.1016/j.seizure.2015.07.001
url https://ddd.uab.cat/record/299412
https://dx.doi.org/urn:doi:10.1016/j.seizure.2015.07.001
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by-nc-nd/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Dipòsit Digital de Documents de la UAB
instname:Universitat Autònoma de Barcelona
instname_str Universitat Autònoma de Barcelona
reponame_str Dipòsit Digital de Documents de la UAB
collection Dipòsit Digital de Documents de la UAB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869425219559489536
score 15,812429

Registos relacionados